49 related articles for article (PubMed ID: 18409068)
21. Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling.
Sallam AA; Mohyeldin MM; Foudah AI; Akl MR; Nazzal S; Meyer SA; Liu YY; El Sayed KA
Org Biomol Chem; 2014 Jul; 12(28):5295-303. PubMed ID: 24927150
[TBL] [Abstract][Full Text] [Related]
22. Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Pohorelic B; Singh R; Parkin S; Koro K; Yang AD; Egan C; Magliocco A
Breast Cancer Res Treat; 2012 May; 133(1):201-14. PubMed ID: 21894461
[TBL] [Abstract][Full Text] [Related]
23. Paxillin modulates squamous cancer cell adhesion and is important in pressure-augmented adhesion.
Conway WC; Van der Voort van Zyp J; Thamilselvan V; Walsh MF; Crowe DL; Basson MD
J Cell Biochem; 2006 Aug; 98(6):1507-16. PubMed ID: 16552730
[TBL] [Abstract][Full Text] [Related]
24. Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: the pivotal role of focal adhesion kinase signalling.
Jiang WG; Ye L; Ji K; Ruge F; Wu Y; Gao Y; Ji J; Mason MD
Oncol Rep; 2013 Sep; 30(3):1405-13. PubMed ID: 23828123
[TBL] [Abstract][Full Text] [Related]
25. Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.
Wu Y; He L; Zhang L; Chen J; Yi Z; Zhang J; Liu M; Pang X
J Pharmacol Exp Ther; 2011 Nov; 339(2):403-11. PubMed ID: 21828260
[TBL] [Abstract][Full Text] [Related]
26. A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways.
Chen JY; Tang YA; Huang SM; Juan HF; Wu LW; Sun YC; Wang SC; Wu KW; Balraj G; Chang TT; Li WS; Cheng HC; Wang YC
Cancer Res; 2011 Jan; 71(2):473-83. PubMed ID: 21224350
[TBL] [Abstract][Full Text] [Related]
27. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.
Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G
J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066
[TBL] [Abstract][Full Text] [Related]
28. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.
Purnell PR; Mack PC; Tepper CG; Evans CP; Green TP; Gumerlock PH; Lara PN; Gandara DR; Kung HJ; Gautschi O
J Thorac Oncol; 2009 Apr; 4(4):448-54. PubMed ID: 19240653
[TBL] [Abstract][Full Text] [Related]
29. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.
El Touny LH; Vieira A; Mendoza A; Khanna C; Hoenerhoff MJ; Green JE
J Clin Invest; 2014 Jan; 124(1):156-68. PubMed ID: 24316974
[TBL] [Abstract][Full Text] [Related]
30. Proteasome regulation by reversible tyrosine phosphorylation at the membrane.
Chen L; Zhang Y; Shu X; Chen Q; Wei T; Wang H; Wang X; Wu Q; Zhang X; Liu X; Zheng S; Huang L; Xiao J; Jiang C; Yang B; Wang Z; Guo X
Oncogene; 2021 Mar; 40(11):1942-1956. PubMed ID: 33603165
[TBL] [Abstract][Full Text] [Related]
31. Saracatinib prompts hemin-induced K562 erythroid differentiation but suppresses erythropoiesis of hematopoietic stem cells.
Ding L; Chen D; Li Y; Xie Y; Sun X; Wang D
Hum Cell; 2024 May; 37(3):648-665. PubMed ID: 38388899
[TBL] [Abstract][Full Text] [Related]
32. Murine breast cancer mastectomy model that predicts patient outcomes for drug development.
Katsuta E; Rashid OM; Takabe K
J Surg Res; 2017 Nov; 219():310-318. PubMed ID: 29078898
[TBL] [Abstract][Full Text] [Related]
33. Normalization and statistical analysis of multiplexed bead-based immunoassay data using mixed-effects modeling.
Clarke DC; Morris MK; Lauffenburger DA
Mol Cell Proteomics; 2013 Jan; 12(1):245-62. PubMed ID: 23071098
[TBL] [Abstract][Full Text] [Related]
34. Role of estrogen receptor signaling in breast cancer metastasis.
Saha Roy S; Vadlamudi RK
Int J Breast Cancer; 2012; 2012():654698. PubMed ID: 22295247
[TBL] [Abstract][Full Text] [Related]
35. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Rexer BN; Ham AJ; Rinehart C; Hill S; Granja-Ingram Nde M; González-Angulo AM; Mills GB; Dave B; Chang JC; Liebler DC; Arteaga CL
Oncogene; 2011 Oct; 30(40):4163-74. PubMed ID: 21499296
[TBL] [Abstract][Full Text] [Related]
36. Quantification of focal adhesion kinase activation loop phosphorylation as a biomarker of Src activity.
Ciccimaro E; Hanks SK; Blair IA
Mol Pharmacol; 2009 Mar; 75(3):658-66. PubMed ID: 19098120
[TBL] [Abstract][Full Text] [Related]
37. Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Jones RJ; Young O; Renshaw L; Jacobs V; Fennell M; Marshall A; Green TP; Elvin P; Womack C; Clack G; Dixon JM
Breast Cancer Res Treat; 2009 Mar; 114(2):211-21. PubMed ID: 18409068
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.
Rajeshkumar NV; Tan AC; De Oliveira E; Womack C; Wombwell H; Morgan S; Warren MV; Walker J; Green TP; Jimeno A; Messersmith WA; Hidalgo M
Clin Cancer Res; 2009 Jun; 15(12):4138-46. PubMed ID: 19509160
[TBL] [Abstract][Full Text] [Related]
39. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530.
Green TP; Fennell M; Whittaker R; Curwen J; Jacobs V; Allen J; Logie A; Hargreaves J; Hickinson DM; Wilkinson RW; Elvin P; Boyer B; Carragher N; Plé PA; Bermingham A; Holdgate GA; Ward WH; Hennequin LF; Davies BR; Costello GF
Mol Oncol; 2009 Jun; 3(3):248-61. PubMed ID: 19393585
[TBL] [Abstract][Full Text] [Related]
40. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
